initial public offerings (IPOs) trading on American exchanges

Thursday, January 9, 2014

MacroGenics (MGNX) began trading on the NASDAQ on 10 October 2013

The Rockville, Maryland, company is developing monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. It does not have any approved drugs and its most advanced experimental drug is in mid-stage clinical testing.

MacroGenics follows at least 30 biotech companies that have gone public in 2013, which has marked a comeback for the IPO market in life sciences after the deals became scarce in the aftermath of the 2008 financial crash. (For an update on the 2013 IPO trend, check out this feature.)

A comeback story itself, MacroGenics recovered from a busted partnership with Eli Lilly ($LLY) after a late-stage trial failure involving their preventive therapy for Type 1 diabetes called teplizumab in 2010. Its recovery resulted from a string of partnerships on next-gen antibody drugs with Pfizer ($PFE), Servier, Gilead ($GILD) and Boehringer Ingelheim. The company says it is hunting for a new collaborator for teplizumab too after recent upbeat results in a midstage study.

MacroGenics CEO & co-founder Dr. Scott Koenig

MacroGenics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. Its products include Margetuximab, a monoclonal antibody that targets human epidermal growth factor receptor 2-expressing tumors, including breast, gastroesophageal, bladder, and other cancers; MGA271, an Fc-optimized monoclonal antibody for various solid tumor types; MGD006, a humanized dual affinity re-targeting (DART) molecule for the treatment of hematologic cancers; and MGD007, a DART protein to treat colorectal cancer. The company's products also comprise Teplizumab, a humanized anti-CD3 monoclonal antibody for the treatment of Type 1 Diabetes; and MGD010, a DART-based molecule for autoimmune diseases. The company has strategic collaborations primarily with Les Laboratoires Servier and Institut de Recherches Servier; Gilead Sciences, Inc.; Boehringer Ingelheim International GmbH; and Pfizer, Inc. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.


9640 Medical Center Drive
United States 

Key stats and ratios

Q2 (Jun '13)2012
Net profit margin-2.76%13.10%
Operating margin-2.44%12.86%
EBITD margin-14.36%
Return on average assets-2.96%14.36%

No comments:

Post a Comment